Zacks Investment Research upgraded shares of Ra Pharmaceuticals (NASDAQ:RARX) from a sell rating to a hold rating in a research report report published on Thursday, Zacks.com reports.
According to Zacks, “Ra Pharmaceuticals, Inc. is a biopharmaceutical company. It involved in the discovery and development of novel therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system. Ra Pharmaceuticals, Inc. is based in Cambridge, Massachusetts. “
RARX has been the topic of several other reports. Svb Leerink began coverage on shares of Ra Pharmaceuticals in a research note on Wednesday, May 22nd. They set an outperform rating and a $33.00 target price on the stock. SunTrust Banks raised their price objective on shares of Ra Pharmaceuticals to $42.00 and gave the company a buy rating in a research note on Friday, May 17th. Jefferies Financial Group raised their price objective on shares of Ra Pharmaceuticals from $40.00 to $45.00 and gave the company a buy rating in a research note on Tuesday, June 18th. Leerink Swann began coverage on shares of Ra Pharmaceuticals in a research note on Wednesday, May 22nd. They issued an outperform rating and a $23.30 price objective on the stock. Finally, Raymond James lowered shares of Ra Pharmaceuticals from a strong-buy rating to a market perform rating in a research note on Monday, July 29th. Two analysts have rated the stock with a hold rating, nine have assigned a buy rating and two have given a strong buy rating to the company. The company has an average rating of Buy and an average target price of $37.73.
NASDAQ RARX traded down $0.35 on Thursday, hitting $32.24. 262 shares of the company were exchanged, compared to its average volume of 553,472. The stock has a market capitalization of $1.36 billion, a P/E ratio of -15.57 and a beta of 1.23. Ra Pharmaceuticals has a 12 month low of $8.67 and a 12 month high of $36.96. The stock’s fifty day moving average is $30.78. The company has a debt-to-equity ratio of 0.02, a quick ratio of 20.10 and a current ratio of 20.10.
Ra Pharmaceuticals (NASDAQ:RARX) last issued its earnings results on Thursday, May 9th. The company reported ($0.45) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.47) by $0.02. As a group, research analysts anticipate that Ra Pharmaceuticals will post -1.8 earnings per share for the current year.
In related news, insider Simon Read sold 10,000 shares of the firm’s stock in a transaction dated Wednesday, July 17th. The shares were sold at an average price of $32.95, for a total transaction of $329,500.00. Following the transaction, the insider now directly owns 16,234 shares of the company’s stock, valued at $534,910.30. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Ramin Farzaneh-Far sold 10,595 shares of the firm’s stock in a transaction dated Monday, July 15th. The shares were sold at an average price of $33.10, for a total transaction of $350,694.50. Following the transaction, the insider now directly owns 8,521 shares in the company, valued at $282,045.10. The disclosure for this sale can be found here. Insiders have sold 33,452 shares of company stock worth $970,463 over the last three months. 4.30% of the stock is owned by insiders.
Hedge funds and other institutional investors have recently bought and sold shares of the stock. Group One Trading L.P. purchased a new stake in Ra Pharmaceuticals during the first quarter worth about $34,000. Legal & General Group Plc increased its holdings in Ra Pharmaceuticals by 57.7% during the fourth quarter. Legal & General Group Plc now owns 3,063 shares of the company’s stock worth $56,000 after buying an additional 1,121 shares during the last quarter. Great West Life Assurance Co. Can purchased a new stake in Ra Pharmaceuticals during the fourth quarter worth about $63,000. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in Ra Pharmaceuticals by 163.0% during the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,014 shares of the company’s stock worth $68,000 after buying an additional 1,868 shares during the last quarter. Finally, BNP Paribas Arbitrage SA purchased a new stake in Ra Pharmaceuticals during the first quarter worth about $88,000. Institutional investors and hedge funds own 95.15% of the company’s stock.
Ra Pharmaceuticals Company Profile
Ra Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system. The company's peptide chemistry platform enables the production of synthetic macrocyclic peptides that combine the diversity and specificity of antibodies with the pharmacological properties of small molecules.
Read More: Hedge Funds
Get a free copy of the Zacks research report on Ra Pharmaceuticals (RARX)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Ra Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ra Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.